Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead wins reversal...

    Gilead wins reversal of 2.54 billion dollars hepatitis C drug patent verdict

    Written by Ruby Khatun Khatun Published On 2018-02-19T09:45:46+05:30  |  Updated On 16 Aug 2021 5:26 PM IST

    A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.


    The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck's patent was invalid. He said it did not meet a requirement that it disclose how to make the treatment it covered without undue experimentation.


    Gilead in a statement on Saturday said it always believed the patent was invalid and was pleased the judge confirmed that opinion.


    Merck in a statement said it planned to appeal and believed the judge's ruling did not reflect the facts of the case.



    The December 2016 verdict followed a trial in which jurors found that Merck's patent on hepatitis C treatments, which it acquired in 2014 when it bought Idenix Pharmaceuticals, was valid.

    Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure.


    Direct-acting antivirals, such as Gilead's Sovaldi and Harvoni, have revolutionized treatment, with cure rates of more than 90 percent shown in clinical trials.


    But there was a backlash from health insurers and other payors when Gilead launched Sovaldi at a price of $84,000 for a 12-week course.


    Foster City, California-based Gilead reported that in 2017 it earned $9.1 billion on its four products to treat hepatitis C, including Harvoni and Sovaldi.


    Idenix, the original holder of the patent at issue in the lawsuit, sued Gilead in 2013 in an effort to block the launch of Sovaldi, which was approved by the U.S. Food and Drug Administration in December of that year.


    Harvoni, which combines Sovaldi's active ingredient, sofosbuvir, with another drug, was approved in October 2014.


    Merck sells its own hepatitis C drug, Zepatier. The company won a $200 million jury verdict last March in a separate patent infringement case against Gilead over hepatitis C drugs.


    But in June 2016, a federal judge in San Jose, California, overturned that verdict after finding that Merck engaged in a pattern of unethical conduct, including lying under oath. Merck has disputed the judge's ruling and is appealing.


    The case is Idenix Pharmaceuticals LLC et al v. Gilead Sciences Inc, U.S. District Court, District of Delaware, No. 14-cv-00846.





    (Reporting by Nate Raymond in Boston; Editing by Bill Trott and Matthew Lewis)




    GileadGilead Science IncGilead SciencesHarvonihepatitis C drugIdenix Pharmaceuticals LLCinflammationMerckpatentpatent infringement caseSovaldiU.S. Food and Drug AdministrationZepatier
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok